167 related articles for article (PubMed ID: 35979119)
21. [Gray zone lymphoma: five cases report and literature review].
Zou HS; Zhang HJ; Liu HM; Huang WY; Liu W; Lyu R; Wang TY; Sui WW; Fu MW; Wang Q; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):242-246. PubMed ID: 37356987
[No Abstract] [Full Text] [Related]
22. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
[TBL] [Abstract][Full Text] [Related]
23. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and pathological characteristics and prognosis analysis of gray zone lymphoma].
Liu SZ; Zong XP; Cai WZ; He HJ; Ma ZX; Li JQ; Li CX; Wu DP
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):69-73. PubMed ID: 38178771
[TBL] [Abstract][Full Text] [Related]
25. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
27. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.
Shi Y; Zhou P; Han X; He X; Zhou S; Liu P; Yang J; Zhang C; Gui L; Qin Y; Yang S; Zhao L; Yao J; Zhang S
Chin J Cancer; 2015 Sep; 34(11):522-30. PubMed ID: 26370464
[TBL] [Abstract][Full Text] [Related]
28. Incidence and Risk Factors of Infections Among Diffuse Large B-cell Lymphoma and Classical Hodgkin's Lymphoma Patients in a Tertiary Care Center in Saudi Arabia: A Retrospective Cohort Study.
Alelyani RH; Alghamdi AH; Almughamisi TA; Alshareef AM; Kadasa AN; Alrajhi AM; Alburayk AK; Barefah AS; Radhwi OO; Almohammadi AT; Bahashawan SM; AlAhwal HM
Cureus; 2023 Mar; 15(3):e35922. PubMed ID: 36911585
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
30. Histopathological difficulties in an adolescent lymphoma patient.
Magyari F; Barna S; Miltényi Z; Rajnai H; Csomor J; Udvardy M; Illés Á; Váróczy L
Pathol Oncol Res; 2015 Jan; 21(1):213-7. PubMed ID: 24985032
[TBL] [Abstract][Full Text] [Related]
31. Malignant lymphoma of the vagina successfully treated with rituximab, adryamicin, cyclophosphamide, vincristine sulfate, and prednisolone.
Nasu K; Okamoto M; Nishida M; Takai N; Narahara H
Eur J Gynaecol Oncol; 2012; 33(2):219-22. PubMed ID: 22611969
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
33. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
34. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Dührsen U; Müller S; Hertenstein B; Thomssen H; Kotzerke J; Mesters R; Berdel WE; Franzius C; Kroschinsky F; Weckesser M; Kofahl-Krause D; Bengel FM; Dürig J; Matschke J; Schmitz C; Pöppel T; Ose C; Brinkmann M; La Rosée P; Freesmeyer M; Hertel A; Höffkes HG; Behringer D; Prange-Krex G; Wilop S; Krohn T; Holzinger J; Griesshammer M; Giagounidis A; Raghavachar A; Maschmeyer G; Brink I; Bernhard H; Haberkorn U; Gaska T; Kurch L; van Assema DME; Klapper W; Hoelzer D; Geworski L; Jöckel KH; Scherag A; Bockisch A; Rekowski J; Hüttmann A;
J Clin Oncol; 2018 Jul; 36(20):2024-2034. PubMed ID: 29750632
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.
Terao T; Yuda J; Yamauchi N; Guo YM; Shimada K; Sugano M; Ishii G; Minami Y
Mol Clin Oncol; 2021 Jun; 14(6):125. PubMed ID: 33936598
[TBL] [Abstract][Full Text] [Related]
36. A case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a Korean child.
Ahn JY; Seo YH; Park PW; Kim KH; Park MJ; Jeong JH; Park SH; Song YH
Ann Lab Med; 2012 Mar; 32(2):162-6. PubMed ID: 22389885
[TBL] [Abstract][Full Text] [Related]
37. Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19?
Yilmaz F; Yasar S; Tuncali MC; Akin S
Semin Oncol; 2021; 48(4-6):279-282. PubMed ID: 34895738
[TBL] [Abstract][Full Text] [Related]
38. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M
Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203
[TBL] [Abstract][Full Text] [Related]
39. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
